Clinical Trials

FDA Approves GammaPod for Breast Cancer Treatment

The U.S. Food and Drug Administration has approved a new breast cancer treatment machine that uses gamma rays to target tumors without harming healthy tissue.

NCCN Updates Clinical Practice Guidelines for Hodgkin Lymphoma

The National Comprehensive Cancer Network has issued updated guidelines for Hodgkin lymphoma, which focus on the management of HL using existing treatments and the need for long-term follow-up after treatment completion.

Roche Receives FDA Approval for Alecensa

Things are looking up for ALK-positive NSCLC patients, thanks to the recent FDA approval of Alecensa (alectinib), a highly selective ALK inhibitor that was shown to reduce the risk of disease worsening or death by 47% compared with crizotinib.

Managing Atrial Fibrillation and Preventing Stroke

Patients with atrial fibrillation are seen with increasing frequency by clinicians. Can it be cured? How must it be managed? How can clinicians prevent stroke in patients with a-fib? Dr. Wazni addresses these questions in our latest video.

Let the Patient Decide: Postoperative A-Fib Rhythm and Rate Strategies Are Equivalent

  • New multinational study of more than 500 patients found no clear superiority of either strategy.
  • The incidence of serious thromboembolic events was low, 2%, and did not differ between the arms.
  • More patients in the rate control arm met protocol-specified indications for anticoagulation compared with the rhythm control arm.

Weight Loss, The CABANA Trial, and the Future of Atrial Fibrillation

In this video, Dr. Oussama Wazni addresses the implications of weight loss, bariatric surgery, and the ongoing CABANA trial on the future of treatment of refractory atrial fibrillation.

Weight Loss, The CABANA Trial, and the Future of Atrial Fibrillation

In this video, Dr. Oussama Wazni addresses the implications of weight loss, bariatric surgery, and the ongoing CABANA trial on the future of treatment of refractory atrial fibrillation.

Health Effects of Loneliness and Social Isolation: A Brief Literature Review

Following is a selection of the recent published literature on the relationship between feelings of loneliness, social isolation, and rates of morbidity and mortality.

  • Having social connections improves peoples’ odds of survival by 50% on average.
  • Living alone increased the likelihood of mortality the most, 32%, while social isolation raised the risk by 29% and loneliness by 26%.
  • Simply living with someone else increased survival by nearly 20%.
  • Extensive social integration nearly doubled the odds of survival.

 

Mobile Apps Found to Improve Management of Chronic Conditions

  • Systematic review of randomized, controlled trials finds that mobile apps can benefit patients with chronic diseases.
  • Review included 9 RCTs.
  • Disease states included diabetes mellitus, cardiovascular diseases, and chronic lung diseases.
  • Interventions ranged from automatic text messages to enhanced clinician contact.

Popular Commercial Sports Drinks Are a Scam

  • The hugely popular commercial sports drinks have no effect on performance or muscle cramping.
  • The only potential performance benefit of drinks like Powerade or Gatorade may be the sugars they contain.
  • There are no scientific data to support the efficacy of low-dose electrolytes in boosting performance.
  • No data exist to support the notion that electrolytes (at the dosages in the commercial drinks) prevent muscle cramping.
  • Evidence appears to support the “altered neuromuscular control” hypothesis as well as other causes and solutions.

Data on Two New Therapies Offer Hope for Myelofibrosis Therapy

  • Data from ASH and ASCO offer new hope for patients with myelofibrosis.
  • Two new oral multikinase inhibitors mark significant advances.
  • Pacritinib and ruxolitinib demonstrated ability to reduce spleen volume by >35%.
  • Data from PERSIST and COMFORT trials are promising.

 

Study Compares 4 Adjuvant Chemotherapies for Resected NSCLC

  • Researchers treated all patients with cisplatin with or without vinorelbine, docetaxel, gemcitabine or pemetrexed.
  • Study examined effects of therapy in patients previously treated with bevacizumab.
  • All patients had non-squamous non-small cell lung cancer.
  • Study was not randomized.

Study Compares 4 Adjuvant Chemotherapies for Resected NSCLC

  • Researchers treated all patients with cisplatin with or without vinorelbine, docetaxel, gemcitabine or pemetrexed.
  • Study examined effects of therapy in patients previously treated with bevacizumab.
  • All patients had non-squamous non-small cell lung cancer.
  • Study was not randomized.

Off-Hour Admissions Pose Significant Threats to Patient Well Being, Increasing Costs

  • Risk associations varied considerably with disease state.
  • Off-hour admission was strongly associated with increased mortality for aortic aneurysm, breast cancer leukemia, respiratory neoplasm, pancreatic cancer, malignant neoplasm of genitourinary organs, colorectal cancer, pulmonary embolism, arrhythmia and cardiac arrest, and lymphoma.
  • Patients can expect significantly better outcomes with on-hour admissions for a wide variety of disorders.
  • Improved outcomes in the noted disorder.

P-Value Is Meaningless—About Half the Time

  • A P-value ≤0.05 does not equate to scientific or policy importance.
  • The P-value ≤0.05 has been called an arbitrary threshold, and said not to equate with statistical significance.
  • The focus on statistical significance has caused researchers to troll the data for findings that provide a P-value ≤0.05.
  • Assigning statistical significance to a P-value ≤0.05 in medicine has been said to have cause harm to patients with serious diseases.
  • P-values do not measure the probability that the studied hypothesis is true, or the probability that the data were produced by random chance alone